From Pathophysiology Towards Immnune-Based Interventions in HIV Infection
The team 16 of the INSERM Unit U955 was created in 2007 by Pr Yves Lévy and is now headed by Pr JD Lelièvre. The team is studying HIV pathophysiology from upstream to translational research in the field of immune interventions and vaccines. The research activity of the team is closely linked to the department of clinical immunopathology. This department has been involved in more than 20 clinical trials in the field of HIV and primary immunodeficiencies, and more than 1000 HIV-infected patients are followed in this clinical department. In 2007, the clinical department extended its clinical research program by the creation of a Clinical Center of HIV Vaccinology aiming at recruiting healthy volunteers and developing an HIV-vaccine clinical trials program. Therefore, extensive clinical opportunities have been available, allowing thus the group to extensively publish on the topic of Immune-Based Therapies and HIV physiopathology.
More recently, in the context of the HIV vaccine program of the ANRS (French National Agency of Research on HIV and hepatitis), the team 16 has extended its technology capacity and expertise by the creation of a platform (Mondor Immunology Center; M.I.C) to perform key end-point immune assays aimed to evaluate human immune responses in immunotherapeutic and vaccine clinical trials. In 2011, a new step of the ANRS vaccine program was achieved by the creation of the Vaccine Research Institute (VRI), lauréat A+ Labex “investissement d’avenir”. Y. Lévy is the PI and coordinator of the VRI on behalf of the ANRS and UPEC. The VRI is a labex located in Mondor with inside and outside teams aimed to face the challenges to develop effective vaccines against HIV and HCV. This research program is implemented by a large network of key international opinion leaders in this field through a unique collaborative network and with a central strategic plan.
Correlations between vaccine-elicited immune responses and the magnitude of viral rebound post c-ART cessation in the anti HIV therapeutic trial DALIA (Transcriptomic analysis)
More specifically, the aims of the team are: i) to understand how and why HIV pathophysiology remains a major clinical problem despite the advent of several generations of potent antiviral drugs; ii) to develop innovative immune interventions such as cytokines, immunomodulators and vaccines aimed at preventing either HIV infection or persistent pathogenesis. Our strategy is to develop in vitro models, to exploit what we can learn from longitudinal follow up of large cohorts of patients at various stages of the disease and following immune interventions in preclinical or clinical studies. This strategy benefits also from a “systems biology” approach allowing a large exploration of hypotheses from limited amount of human materials (blood, sera, cells or gut and skin biopsies) and the development of new vaccines, the validation of which brings also new knowledge on the physiology and immune correlates of protection. Our path is to investigate mechanisms of immune restoration, the effects of immune modulation strategies, and the consequences of immune interventions.
Work program of the team includes three main aspects :
Immune restoration (PI:Pr JD Lelièvre, Dr N Seddiki)
This part of the program is aimed at pursuing the investigation of the mechanisms involving IL-7 and Notch in the generation of early thymic precursors but also aspect of regulation of T cell homeostasis during HIV infection. Currently topics developed here are 1. Interaction of Notch and IL7 in T cell development 2. Analysis of CD34 potential during HIV infection 3. Determination of the role of SamHD1 in peripheral T cell during HIV infection
Immune regulation (PI: Pr S Hue, Dr H Hocini, Dr C Lacabaratz, Pr JD Lelièvre, Dr N Seddiki)
A large part of our program aims at understanding the regulation of effector T cell responses with a specific focus on Treg in the periphery and at mucosal sites in HIV infected individuals, co-infected or not with other pathogens. The Current main topics developed are: 1. : Investigation of the interaction between Regulatory/effector balance and epithelial damage in HIV + individuals; 2. B cells response and impact on the gut integrity in HIV infected patients; 3. Study of the role of Treg in vaccination; 4. Study of Treg/Th17 balance during Mycobacterium Tuberculosis infection in patients co-infected or not with HIV
In collaboration with the clinical department of dermatology of CHU Henri Mondor (Pr O Chosidow, Pr P Wolkenstein) the team also perform research on hidradenitis suppurativa which is used as a model to of skin inflammation and T cell homeostasis disturbance.
Immune intervention (PI: Dr S Cardinaud, Pr V Godot, Dr H Hocini, Dr C Lacabaratz, Pr JD Lelièvre, Dr G Scarlatti,Pr S. Hue , Dr N Seddiki )
As a part of the VRI our team in collaboration with our clinical department is involved in a large clinical program aiming to develop prophylactic and therapeutic phase I/II HIV prime boost vaccine studies to identify the “best-in-class” strategy that will be developed in phase IIb/II. The vaccine strategy of the VRI focuses on dendritic cells using anti DC targeting vaccines. More specifically, the current topics developed are
1. The study of antibody responses at the mucosal level during HIV infection and vaccination;
2. Study of the role of GILZ protein in the biology of DC and its use to improve DC;
3. Study of the direct impact of Env-anti-DC proteins on both phenotype and function of DCs.
4. Building of prophylactic and therapeutic vaccine trials (clinical department)
Histological aspect of the gut in an early treated patients showing a well-organized B-cell follicle containing a germinal center highlighted by a network of CD21+ FDC
Members of the team are involved in several committees in ANRS (www.anrs.fr/) and Sidaction (https://www.sidaction.org/). They head two master programs dedicated to immunology (http://www.u-pec.fr/pratiques/universite/formation/master-biologie-sante-parcours-immunologie-644220.kjsp) and vaccinology (http://www.u-pec.fr/pratiques/universite/formation/master-biologie-sante-parcours-vaccinologie-644217.kjsp).
HIV, vaccine, Treg, Dendritic cells, GILZ, IL7, CD34, Notch, Mucosal immunity, hidradenitis suppurativa
Levy Y*, Lelievre JD *, L Assoumou, , E Aznar, F Pulido, G Tambussi, M Crespo, A Meybeck, , J-M Molina, C Delaugerre, J Izopet, , G Peytavin, F Cardon, A Diallo, R Lancar, L Béniguel, D Costagliola, Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV-infection : a double-blind randomized controlled trialAnnals of Internal Medicine, 11 february 2020
Aurélie Wiedemann , Emile Foucat, , Hakim Hocini, Cécile Lefebvre, Mélany Durand Miriam Kruger, Alpha Kabinet Keita, Ahidjo Ayouba, , Stéphane Mély, , José-Carlos Fernandez, , Abdoulaye Touré, , Slim Fourati, M.D., Claire Lévy-Marchal, Hervé Raoul, Eric Delaporte , Lamine Koivogui , Rodolphe Thiébaut , Christine Lacabaratz*, and Yves Lévy* for the PostEboGui Study Group Long-lasting severe immune dysfunction in Ebola virus disease survivors.Nature Communications, 2020 , Jul 24, vol 11, 1-11
Surenaud M, Montes M, Lindestam Arlehamn CS, Sette A, Banchereau J, Palucka K, Lelièvre JD, Lacabaratz C, Lévy Y. “Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination.”PLoS Pathog. 2019 Sep 9;15(9):e1008011. doi: 10.1371/journal.ppat.1008011
Thiébaut R, Hejblum BP, Hocini H, Bonnabau H, Skinner J, Montes M, Lacabaratz C, Richert L, Palucka K, Banchereau J, Lévy Y. Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected IndividualsFront Immunol. 2019 Apr 24;10:874. doi: 10.3389/fimmu.2019.00874. eCollection 2019
Lylia Hani, Antoine Chaillon, Marie-Laure Nere, Nicolas Ruffin, Joudy Alameddine, Maud Salmona, José-Luiz Lopez Zaragoza, Davey M. Smith, Olivier Schwartz, Jean-Daniel Lelièvre, Constance Delaugerre, Yves Lévy and Nabila Seddiki “Proliferative memory SAMHD1low CD4+ T cells harbour high levels of HIV-1 DNA with compartmentalized viral populations”PLoS Pathog. 2019 Jun 20;15(6):e1007868. doi: 10.1371/journal.ppat.1007868. eCollection 2019 Jun.
Hakim Hocini, Henri Bonnabau, Christine Lacabaratz, Cécile Lefebvre, Pascaline Tisserand, Emile Foucat, Jean-Daniel Lelièvre, Olivier Lambotte, Asier Sáez-Cirión, Pierre Versmisse, Rodolphe Thiébaut, and Yves Lévy "HIV controllers have low inflammation associated with a strong HIV-specific immune response in blood"J Virol. 2019 Feb 27. pii: JVI.01690-18. doi: 10.1128/JVI.01690-18
Flamar AL, Bonnabau H, Zurawski S, Lacabaratz C, Montes M, Richert L, Wiedemann A, Galmin L, Weiss D, Cristillo A, Hudacik L, Salazar A, Peltekian C, Thiebaut R, Zurawski G, Levy Y. HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates.PLoS One. 2018 Nov 30;13(11):e0207794. doi: 10.1371/journal.pone.0207794. eCollection 2018
Cheng L, Wang Q, Li G, Banga R, Ma J, Yu H, Yasui F, Zhang Z, Pantaleo G, Perreau M, Zurawski S, Zurawski G, Levy Y, Su L TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirsJ Clin Invest. 2018 Oct 1;128(10):4387-4396. doi: 10.1172/JCI99005
Palich R, Ghosn J, Chaillon A, Boilet V, Nere ML, Chaix ML, Delobel P, Molina JM, Lutch F, Bouchaud O, Rieux V, Thiebaut R, Levy Y, Delaugerre C, Lelievre JD; « Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial ».AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002058.
Planchais C, Hocqueloux L, Ibanez C, Gallien S, Copie C, Surenaud M, Kök A, Lorin V, Fusaro M, Delfau-Larue MH, Lefrou L, Prazuck T, Lévy M, Seddiki N, Lelièvre JD, Mouquet H, Lévy Y, Hüe S. « Early Antiretroviral Therapy Preserves Functional Follicular Helper T and HIV-Specific B Cells in the Gut Mucosa of HIV-1-Infected Individuals.»J Immunol. 2018 Apr 9. pii: ji1701615. doi: 10.4049/jimmunol.1701615.
- Responsable : Jean-Daniel Lelièvre
- Chercheur : Célia Ait-Mouhoub, Barbara Cagniard
- Enseignant-Chercheur : Michele Boniotto, Sébastien Gallien, Véronique Godot, Sophie Hüe, Jean-Daniel Lelièvre, Yves Lévy, Gepy Pantaleo
- Post doctorant : Séverin Coléon, Nour Ghazzaui, Jose-Luis Lopez-Zaragoza, Giovanna Melica, Yadira Pastor, William Vindrios, Saliha Ysmail Dahlouk
- Doctorant : Valentina Ceglia, Nora Deluce, Lydie Dieudonne, Adèle Hammoudi, Sophie Lalevée, Cécile Nait-Meddour, Mubashira Tariq
- Ingénieur : Fabiola Blengio, Amel Bouakane, Sylvain Cardinaud, Marie Dechenaud, Léa Dupaty, Emile Foucat, Lydia Guillaumat, Hakim Hocini, Francette Jean-louis, Christine Lacabaratz, Cécile Lefebvre, Florence Picard, Véronique Rieux, Mathieu Surenaud, Pascaline Tisserand, Aurélie Wiedemann
- Technicien : Corinne Krief-Bouillet
- Gestionnaire : Eric Scoazec
- Administratif : Mireille Centlivre, Laurent Hanot
- Stagiaire : Maya-Alix Esso, Gabriel Windels
Detailled organisation of the team
IMRB – Inserm U955
From Pathophysiology Towards Immnune-Based Interventions in HIV Infection (Team 16)
Building R – 1st floor
Hôpital Henri Mondor
51, avenue du Maréchal De Lattre de Tassigny
Administrative assistant – Contact
Tel. : +33-1 49 81 28 52
Hepatocellular carcinoma is responsible for one third of cancer deaths worldwide, and most often develops in a context of chronic inflammation. While the immune microenvironment of tumours plays a decisive role in their evolution and is the subject of numerous studies, the role of immunity during the early stages of carcinogenesis remains little studied. In […]Read more
The family Bunyaviridae is a large but unfamiliar group of viruses with more than 300 members with a spherical and helical envelope. Viruses of this family can infect a wide range of hosts, from mosquitoes to marsupials and from thrips to tomatoes. Several of the Bunyaviridae cause serious disease in humans; they represent a growing […]Read more
VRI (Vaccine Research Institute)/ INSERM/UPEC (U955, IMRB) in collaboration with several Inserm and IRD teams has just published a study in Nature Communications on 24 July showing that Ebola survivors suffer serious immune system sequelae two years after their disease. Continuing to wreak havoc in the Democratic Republic of Congo four years after the […]Read more